How can outcomes be improved in patients with molecularly-defined high-risk AML?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Alice Mims, Ohio State University Comprehensive Cancer Center - The James, Columbus, US. We asked, How can outcomes be improved in patients with molecularly-defined high-risk acute myeloid leukemia (AML)?

Mims outlines the use of the 2022 European LeukemiaNet risk classification in molecularly defining high-risk AML and discusses the importance of cytogenetics and sequencing at the time of diagnosis to guide treatment decisions and determine eligibility for clinical trials. Mims goes on to discuss data presented at ASH on patients with TP53 mutations, FLT3-ITD, and KMT2A rearrangements treated with therapeutics including azacitidine, venetoclax, magrolimab, eprenetapopt (APR-246), gilteritinib, and revumenib (SNDX-5613).